Biotech Down Under with BiomeBank's Dr. Sam Costello

Business Of Biotech

We love to hear from our listeners. Send us a message.

Merry Christmas, Business of Biotechers! On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, a former gastroenterologist-turned managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind, anywhere in the world. In a segment of biotech that’s been particularly battered of late, that’s a big, big win. We also talked about what’s behind Australia’s foray onto the global biotech scene, the public/private partnerships supporting that growth, why U.S. biotechs, in particular, are flocking there to conduct clinical trials, and whether Foster’s is really Australian for beer. Don’t miss it!

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

บท

1. The Microbiome Therapeutics Market in Biotech (00:00:00)

2. Exploring the Biotech Scene in Australia (00:16:06)

3. Australian Biotech (00:23:37)

4. Potential and Challenges of Microbiome Therapeutics (00:39:03)

5. Biobank Investor Paradigm and Future Plans (00:53:44)